HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Earthly Body

This article was originally published in The Rose Sheet

Executive Summary

"Preeminent [maker] of hemp-based body care" launches new Dare to be Bare shaving/skin care duo "just in time for bikini season." Touted as "the natural answer to shaving bumps and waxing irritation," Dare to be Bare consists of Shave Cream ($11 for 8 oz.) and Miracle Oil ($11 for 1 oz.), sold separately or together in a packaged combination set ($20). Shave Cream - available in company's Original unisex scent and in Skinny Dip, "a delightful concoction of cotton candy and vanilla" - softens hair and conditions skin with nourishing hemp seed oil and Argan oil, "protecting it from shave rashes and skin bumps," according to recent release. Miracle Oil is formulated with 100% natural oils such as tea tree and hemp oil, Chatsworth, Calif.-based Earthly Body says, claiming "women will find that the Miracle Oil soothes the bikini line and prevents itching as hair re-grows." Earthly Body notes online that hemp seed oil has "the highest concentration of essential fatty acids of any essential oil, as well as the perfect balance of omega-3 and omega-6 EFAs.

You may also be interested in...

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Generics Leaders Trade Places At The Top

In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts